Tag: the war on (some) drugs

EXPLORING SEX AND PSYCHEDELICS

The connection between sex and psychedelics dates back to the sexual liberation movement throughout the 1960s and 70s. Psychedelics, in particular LSD, were associated with loosened sexual inhibitions and the resolution of past sexual trauma. Inspired by Timothy Leary’s infamous calls to ‘turn up, tune in, drop out’, psychedelics appeared as a tool for pleasure, love and self-expression. 

For sex guru Annie Sprinkle, using psychedelics through the 60s, 70s and 80s had profound positive impacts on her sex life. From opening doors to alternative realities, to increasing connectedness and sexual satisfaction between partners, Annie calls them her ‘greatest sexual educators’. 

She notes that the connection between sex and psychedelics is much deeper than arousal. Through each experience the user gains new information, allowing them to see themselves from a new perspective. This, in turn, can inform the individual’s sexual life.

Even though psychedelics remain illegal across much of the world, anecdotal evidence suggests that using psychedelics to enhance sexual experiences is still just as popular as it once was. However, as sex on drugs has inevitably been labelled a high-risk activity , there is a clear lack of hard-line statistics to back up such an assumption. 

Keep reading

How Cartels Infiltrate The Border Patrol

Goat Canyon is a dry valley of crystalline rocks in the east of San Diego county named after the desert bighorns that roam. It was the perfect spot, Border Patrol agent Noe Lopez told his contact, to move dope through. “Honestly, the thing is that there aren’t—there aren’t any cameras,” Lopez said. “Nothing, nothing, nothing.”

Lopez went himself to the store and purchased three backpacks for the smugglers to use. On the first night, he collected one at the border fence with a glint of crystal meth inside. He stashed it in his Border Patrol truck, drove to base, switched it to his private car and then handed it to his connect in a parking lot in exchange for three grand in cash.

The second night he grabbed a bag with seven kilo bricks with the markings of cocaine. His source gave him $7,000 but said the smugglers were uneasy about going over the fence. Lopez said there was nothing to worry about. “If I’m saying, ‘cross now,’ that means that I am taking the responsibility for them to cross.”

But Lopez never made it to the third drop. He was arrested and charged with attempted cocaine and meth trafficking. The source, he discovered, was a DEA informant who had him on tape and the drugs were fake. He plead guilty and got seventy months in prison in 2017.

It was no freak case. In 2023, a judge sentenced agent Oberlin Cortez Peña for waving cars of cocaine through a checkpoint north of McAllen, Texas. In 2014, customs agent Lorne “Hammer” Jones got seven years for letting trucks of dope through San Ysidro. And that’s the tip of the iceberg.

Since the Department of Homeland Security was created in 2002, incorporating Customs and Border Protection, well over a hundred agents and officers have been convicted of trafficking dope or running undocumented migrants. This usually means working with cartels and their affiliates who control drug and human smuggling over the border.

Keep reading

How the FDA approved an antipsychotic that failed to show a meaningful benefit but raised the risk of death

In trials, brexpiprazole failed to provide a clinically meaningful benefit and it increased mortality, but the FDA fast tracked its approval and the sponsor predicts $1bn in annual sales. Robert Whitaker investigates the first licensed antipsychotic for treating agitation in elderly patients with dementia

For years, health officials have tried to rein in the prescribing of atypical antipsychotics to elderly patients with dementia. The practice has been entirely “off label” yet widespread. The US Food and Drug Administration reports that around 60% of patients with Alzheimer’s dementia in residential care have received an off-label prescription for an antipsychotic, benzodiazepine, antidepressant, or anti-epileptic drug. After a 2005 FDA warning that cited a 60-70% increased risk of death associated with antipsychotic drug use, the US Centers for Medicare and Medicaid Services established the National Partnership to Improve Dementia Care in Nursing Homes, a public-private collaboration that sought to “reduce the use of antipsychotics” and “enhance the use of non-pharmacological approaches.”1

But a May 2023 FDA approval of the antipsychotic brexpiprazole for agitation in patients with Alzheimer’s dementia may reverse all of this. At a cost of around $1400 (£1102; €1280) a month, the manufacturers Otsuka and Lundbeck, which jointly brought the “first in class” approval to market, are forecasting an additional $1bn in annual sales of Rexulti.2

Serious questions remain, however, about the harm-benefit balance of Otsuka and Lundbeck’s drug. The drug carries a “boxed warning”—the FDA’s most serious type of warning, informing prescribers of increased mortality. And among four efficacy evaluations across the three prelicensure clinical trials, the highest efficacy observed was a 5.3 point improvement over placebo on a 174 point scale. In the two trials that assessed quality of life, no benefit for either the patient or the caregiver was demonstrated.

“The small benefits do not outweigh serious safety concerns,” said Nina Zeldes, health researcher at the consumer advocacy organisation Public Citizen, addressing the FDA’s advisory committee at its 14 April meeting before the approval.3 “Like other antipsychotics, this is a drug that can kill patients without providing a meaningful benefit.”4

Keep reading

A Netflix Drama Reinforces Pernicious Misconceptions About Pain Treatment

Former New York Times reporter Barry Meier, whose book about OxyContin is the main basis for the Netflix drama Painkiller, acknowledges that the drug is “valuable for treating severe pain caused by cancer or chronic health issues.” The problem, he says, was that OxyContin’s manufacturer, Purdue Pharma, “could only make billions from it by lying, by saying it was good for everyday, common pain.”

Netflix’s six-part miniseries highlights that second point, vividly portraying Purdue Pharma’s reckless marketing of OxyContin. But it dismisses the caveat: that there are legitimate medical uses for this drug and other prescription opioids, which can make life bearable for patients who otherwise would suffer from excruciating pain.

Like the 2022 Hulu drama Dopesick, Painkiller embraces an indiscriminate aversion to opioids. The same attitude has inspired ham-handed restrictions on pain medication, which have helped drive drug-related deaths to record levels while leaving millions of patients to suffer needlessly.

Although Meier’s take on opioids is more nuanced than the one presented by this adaptation of his book, he shares with the screenwriters a desire to pin a complex, long-running social problem on a single villain. That much is clear from the subtitle of his book: “An Empire of Deceit and the Origin of America’s Opioid Epidemic.”

As Meier’s former employer frequently puts it, OxyContin is “widely blamed” for “igniting the opioid crisis.” But is it rightly blamed?

OxyContin, which was introduced in 1996, is an extended-release version of oxycodone, a semisynthetic opioid that had long been available in products such as Percocet and Percodan. OxyContin contained a larger dose of oxycodone, which was supposed to be gradually released over a 12-hour period, such that a patient could obtain steady pain relief by taking two pills a day.

That safeguard, according to labeling approved by the Food and Drug Administration, was “believed” to reduce the drug’s abuse potential. As it turned out, the original design could be readily defeated by crushing the tablets and snorting the powder.

According to federal survey data, however, nonmedical use of prescription pain relievers rose for 11 consecutive years before OxyContin was introduced. And regardless of how appealing it may have been to drug users, OxyContin never accounted for a very large share of the opioid analgesic market.

During litigation, Purdue presented data indicating that OxyContin accounted for just 3.3 percent of pain pills sold in the United States from 2006 through 2012. After adjusting for potency, ProPublica calculated that the product’s “real” market share was more like 16 percent.

Keep reading

Did a dose of LSD spawn some of cinema’s greatest films?

Federico Fellini, one of the greatest filmmakers of the 20th century, attributes much of his success to a single dose of LSD he took in the summer of 1964 ​“during a time of creative crisis”. According to a recent study looking into how this experience influenced his work, the dose was administered by Dr Emilio Servadio, one of the most prominent Italian psychoanalysts of the time. It induced a trip so intense that the filmmaker later needed sedative medication to put it to an end.

Fellini took part in the psychotherapy session directly after he had finished working on his masterpiece 8 ½, and before he started writing his next film Giulietta degli Spiriti. The talking therapy that occurred after the LSD dose was recorded with a magnetophone. The tapes have never been found by researchers, but in an interview with the BBC a year later, Fellini explained how the experience stimulated his creativity by altering his perception of colour and allowing him to perceive colours in an entirely different light.

“The doctor gave me an explanation and I agree with him,” he told a reporter in 1965. ​“He said that an artist lives always in the imagination so the barrier between sensorial reality and his imagination is very vague… I saw colours not like they normally are – we see colours in the objects, you know; we see objects that are coloured. I saw colours detached from the objects. I had for the first time the feeling of the presence of the colours in a detached way.” Fellini’s work after the acid trip was later praised for having ​“supernaturally brilliant colours”.

Fellini’s perception of time was also altered during his trip, which was was reflected in his work post-LSD trip – the authors of the study said his films started to incorporate plots involving ​“puzzling and disorienting flashbacks”. The filmmaker was also said to have had epiphanies during the trip involving space and perception of self, both of which were apparent in his subsequent work. ​“The world depicted in his post-LSD movies includes major changes in the perception of space, time and others,” the study concluded.

Keep reading

World Anti-Doping Agency Experts Say Marijuana Use Violates The ‘Spirit Of Sport’ And Makes Athletes Unfit Role Models

Members of a World Anti-Doping Agency (WADA) panel say that marijuana use by athletes violates the “spirit of sport,” making them unfit role models whose potential impairment could put others at risk.

In an editorial published in the journal Addiction, several members of WADA’s Prohibited List Expert Advisory Group summarized the reasons that the body decided to continue prohibiting cannabis use by athletes in competitions last year amid growing calls to end the policy.

Perspectives were “mixed” over whether marijuana “enhances or has the potential to enhance sport performance,” they wrote. And the group also acknowledged that athletes have reported that cannabis benefits them by “facilitating recovery and reducing pain.”

But in the end, they said that the use of marijuana in competitions violates ethical standards, justifying the ban.

Specifically, the editorial says that cannabis consumption runs counter to the “spirit of sport,” which “encompasses a number of universal values of sport, and four aspects that were particularly relevant to the discussion on cannabis remaining in the list.”

Keep reading

Bipartisan Senators Say Marijuana Legalization Disrupts Cartels In Letter Challenging Proposed Menthol Cigarette Ban

A bipartisan group of U.S. senators are acknowledging that state-level marijuana legalization has disrupted the operations of international drug cartels as they raise concerns with the State Department over plans to ban menthol cigarettes and cap nicotine content.

In a letter sent to Secretary of State Antony Blinken last week, Sens. Mark Warner (D-VA), Bob Casey (D-PA), Bill Cassidy (R-LA), Marco Rubio (R-FL) and Bill Hagerty (R-TN) said that prohibitionist policies for certain tobacco products would benefit the illicit market, which is continually evolving in response to new regulatory policies.

The lawmakers used cannabis as an example of how cartel operations shift depending on whether certain substances are prohibited or regulated. Legalization at the state level, they argued, has reduced demand for illicit marijuana.

“As it has become easier to sell marijuana products in the U.S., Mexican TCOs [transnational criminal organizations] have prioritized trafficking fentanyl and other synthetic drugs that are cheaper to manufacture, easier to transport, and generate more profit,” the senators—none of whom are vocal cannabis legalization advocates—said.

Republican senators, including Cassidy, Rubio and Hagerty, made the same point in a letter to the head of the Food and Drug Administration (FDA) last month, imploring the agency to reconsider its plans to ban menthol cigarettes and cap nicotine content.

“TCOs have expanded their operations to include the production and distribution of cigarettes,” the bipartisan group wrote in the new letter to Blinken. “TCOs more generally have taken advantage of drug smuggling routes to import illegal cigarettes into the U.S., contributing to the significant use of smuggled cigarettes.”

The senators included a list of questions for the secretary of state about how the department is dealing with issues related to illicit tobacco trafficking. They asked about the status of interagency work to combat the problem, how efforts to limit tobacco use could empower traffickers and engagement with international partners to address the problem, for example.

“It is clear that threat actors—from transnational organized crime entities to terrorist organizations—are employing increasingly creative tools to subvert controls imposed by the U.S. and our international partners,” they said. “We appreciate the work that the men and women of the Department of State do in countering these efforts, and urge continued action to address these threats.”

The senators’ point about shifting trends in marijuana trafficking as states legalize is bolstered by a Congressional Research Service (CRS) report that was released last year, showing how demand for illicit cannabis from Mexico has continued to drop as more states open regulated domestic markets.

Keep reading

Ohio’s Local Health Departments Join Marijuana Legalization Opposition Campaign Ahead Of November Vote

An association representing Ohio’s 112 local health departments is opposing a marijuana legalization ballot measure set to go to voters in November, claiming the policy change would only contribute to drug-related problems in the state.

“Making marijuana more accessible through legal recreational use and retail sales hurts Ohio, creates serious new risks for children’s health and makes our workplaces and highways less safe,” the Ohio Association of Health Commissioners warned in a statement Tuesday. “With Ohio’s rates of opiate abuse and overdoses still among the highest in the country, we need to be helping Ohio find solutions to addiction, not facilitating it or the interests of an industry that profits from it.”

Ohio’s secretary of state’s office announced last week that advocates for the legalization measure turned in enough signatures to qualify for the ballot, which prompted statements of support—and opposition—from stakeholders across the state. The health commissioners join the Ohio Children’s Hospital Association and Adolescent Health Association, as well as law enforcement and some business groups, in advocating against the change.

Many of the new opposition group‘s claims treat as settled science issues that other say demand further investigation. For example, a recent federal research from the U.S. Centers for Disease Control and Prevention (CDC) found that teen marijuana use has actually been in decline since legal retailers began opening. And a number of studies have associated cannabis use and legalization with reductions in the use of unregulated opioids, prescription drugs and other regulated substances.

Ohio currently ranks seventh among all U.S. states in terms of drug overdose death rates, after West Virginia, Tennessee, Louisiana, Kentucky, Delaware and New Mexico.

The campaign backing the measure, the Coalition to Regulate Marijuana Like Alcohol, told Marijuana Moment on Tuesday that it’s “confident that Ohioans, just like voters in the states that have come before us, will see through these tired, debunked talking points.”

“Ohio’s current system of prohibition does not work,” said campaign spokesman Tom Haren. “We know that there is an adult-use market in Ohio today. It is called the illicit market. It is completely unregulated, products are not tested and products are not taxed. Also, drug dealers in the illicit market are happy to sell to children without ever checking for ID. This is a reality that is bad for the health of Ohioans.”

In states that have legalized, Haren added, “We know that usage among minors and adolescents does not change. We know that regulation does not adversely affect the workforce, and we also know that it is a boon for state tax revenue.” The measure’s 10 percent proposed tax, for example, “will generate more than $100 million every year to fund substance abuse and addiction treatment.”

In fact the state could see between $257 million and more than $400 million annually in tax revenue through legalization, according to a recent analysis from Ohio State University researchers.

Voters, for their part, appear to be leaning in favor of legalization. A USA TODAY Network/Suffolk University poll published in July found that about 59 percent of Ohioans supported legalizing the possession and sale of cannabis for adults 21 and older. Just 35 percent were opposed.

Republicans officials in Ohio remain divided on the issue. Gov. Mike DeWine said last week that he believes “it would be a real mistake for us to have recreational marijuana,” adding that he visited Colorado following its move to legalize in 2012 and saw what he argued is an “unmitigated disaster.”

Keep reading

GOP Congressman Threatens Indian Tribe With Loss Of Federal Funding Over Marijuana Legalization

A Republican congressman from North Carolina is urging members of the Eastern Band of Cherokee Indians (EBCI) to reject a referendum next month that would legalize marijuana on tribal land, warning that the move would mean a loss of federal funding under a bill he plans to introduce.

In an op-ed published last week in The Cherokee One Feather, Rep. Chuck Edwards (R-NC) acknowledged that Congress cannot stop the EBCI referendum, set for September 7, from going forward. But he appealed to the tribe’s members to vote against it.

“I proudly consider the tribe my friends, and I respect their tribal sovereignty,” the freshman House member wrote. “But there are times when friends disagree, and I must do so regarding this question of legalizing recreational marijuana. The tribe’s rights should not infringe on the overall laws of our nation.”

Passage of the legalization referendum would bring legal cannabis sales within a short drive of many people in North Carolina, where both medical and adult-use marijuana remain illegal under state law. Sales on EBCI land under the proposal would be open to all adults 21 and older, regardless of tribal membership. And as Edwards noted, the tribe has land holdings “all over western North Carolina.”

“To allow our citizens to travel only a few miles to buy and use this common gateway drug,” wrote Edwards, who opposed cannabis reform in North Carolina during his time as a state senator, “would be irresponsible, and I intend to stop it.”

Keep reading

Minnesota Governor Dismisses Claims That State Constitution Lets People Sell Homegrown Marijuana Without A License Following Legalization

The governor of Minnesota is pushing back against a legal argument that the state Constitution allows people to sell their homegrown marijuana without obtaining a license, stating that it was “not our intention” to authorize that type of commerce under the legalization legislation he signed into law this year.

While adults 21 and older may now possess, cultivate and gift cannabis under the law that took effect at the beginning of the month, retailers (beside those operated by tribes) are not expected to open for at least another year. As the law was being drafted, however, some advocates said that Section 7, Article XIII of the Minnesota Constitution gave farmers another option to begin marijuana sales outside of the licensing scheme.

That section, enacted in 1906 after a farmer was penalized for selling melons out of his wagon, states that “any person may sell or peddle the products of the farm or garden occupied and cultivated by him without obtaining a license.”

It doesn’t specify what kinds of products may be sold—and now that cannabis is legal, certain advocates are making the case that the policy is applicable to homegrown marijuana. Others want lawmakers to revise the new legalization law so that it explicitly protects the rights of farmers to sell their own cannabis without a license.

Gov. Tim Walz (D), a strong proponent of the state’s legalization law, said during a press conference last week that he and lawmakers didn’t intend to create that alternative commerce pathway, though he didn’t necessarily speak to the merits of the constitutional argument. He said he hasn’t had any “substance conversations” with legislative experts or commerce officials about the possibility.

Keep reading